Effects of tirofiban on high-sensitivity C-reactive protein and fibrinogen in non-ST-segment elevation acute coronary syndrome patients with medium-risk diabetes

AIM:To explore effects of tirofiban on high-sensitivity C-reactive protein（hs-CRP） and fibrinogen（FIB） in non-ST-segment elevation acute coronary syndromes（STE ACS） patients with medium risk diabetes.METHODS:A total of 248 cases of hospital patients with non-STE ACS were assigned to two groups:129 cases in observation group and 119 cases in control group.Aspirin（300 mg） and clopidogrel（300 mg） were given as initial dose and afterwards aspirin（100 mg/day） and clopidogrel（75 mg/day） as treatment dose.In observation group,tirofiban was additionally given IVI for 2-3 days,together with hypodermic injection of low molecular weight heparin（LMWH）（enoxaparin） 40 mg/12 h.Twelve hours after tirofiban injection suspension,hypodermic injection of LMWH alone was given for another 3-4 days.In control group,hypodermic injection of LMWH enoxaparin 1 mg/（kg·12 h） was given for 5-7 days.Patients’ plasma hs-CRP,FIB and correlation were also examined before and 7,30 and 60 days after treatment.Deaths,nonfatal MI,recurrent chest pain and bleeding conditions were also observed 30 and 60 days after treatment.RESULTS:hs-CRP and FIB levels decreased in both groups.hs-CRP and FIB levels in observation group became lower than those in control group 7 days after treatment.This difference was most significant 30 days after treatment but disappeared 60 days after treatment.hs-CRP and FIB levels in both groups presented a linear positive correlation.Composite ischemic event incidence in observation group was lower than that in control group 30 and 60 days after treatment and no major bleeding events occurred in either group.CONCLUSION:Tirofiban further reduces hs-CRP and FIB levels and lowers composite ischemic event and major bleeding events in non-STE ACS patients with medium-risk diabetes.